Defense Secretary Pete Hegseth announced on July 15, 2026, that all active-duty and reserve component service members aged 30 and older will undergo mandatory annual testosterone screening as part of their routine Periodic Health Assessment, according to a Pentagon memorandum issued the same day. Service members under 30 may request the screening voluntarily. If low testosterone is detected and a physician recommends treatment, testosterone replacement therapy is optional, not required.
The policy, which Hegseth framed in a social media video titled "High-T Department" as optimizing "warfighter readiness," takes effect immediately. It does not distinguish between male and female service members in the written memo's mandatory provision; Snopes reporting confirmed the memo contains no explicit exemption for women, even though testosterone levels and clinical thresholds differ significantly between sexes.
Why This Matters
Testosterone is a physiologically important hormone in both men and women. Clinically diagnosed low testosterone, or hypogonadism, can cause fatigue, decreased muscle mass, reduced bone density, impaired cognition, and mood changes in both sexes. These are symptoms that could plausibly affect military readiness, and there is an established medical literature documenting low testosterone as a treatable condition in appropriate clinical contexts.
But the policy raises substantive medical and policy questions that MedicalDaily's audience deserves to have answered honestly: What does testosterone screening involve? What constitutes clinically low testosterone? Does routine screening of large, generally healthy populations have established clinical benefit? And what distinguishes a clinically appropriate testosterone screening program from one that medicalizes normal age-related hormonal variation?
These questions do not have partisan answers. They are clinical questions.
What We Know So Far
Testosterone deficiency, medically called hypogonadism, is a recognized clinical condition. In men, it is typically defined by serum testosterone levels below a laboratory-specific reference range, often cited as below 300 ng/dL, combined with symptoms attributable to that deficiency. In women, testosterone levels are normally 10 to 20 times lower than in men, and female hypogonadism is defined differently using sex-specific reference ranges.
According to CBS News reporting, Hegseth specifically cited the "high operations tempo and high stress that these service members go through" as a clinical rationale, noting that chronic stress and intense physical demands can suppress testosterone production in otherwise healthy individuals. This is a medically recognized phenomenon: chronic cortisol elevation from prolonged physical or psychological stress can suppress the hypothalamic-pituitary-gonadal axis and reduce testosterone output.
The Periodic Health Assessment in which the screening will be embedded is a comprehensive annual examination already mandatory since 2016. It currently assesses medical condition, behavioral health, mental health, and deployment readiness. Adding a testosterone blood panel to this existing assessment requires only a single additional blood draw.
Where the Policy Applies
The policy applies to all active-duty and reserve component service members aged 30 and older across the Army, Navy, Air Force, Marine Corps, Space Force, and National Guard. The Pentagon memorandum, as described by Snopes and NBC News, does not contain an explicit exemption for female service members, meaning that as written, the mandatory annual screening applies to women over 30 as well. Women account for approximately 17% of active-duty service members.
The New York Times reported that the policy applies to women as well as men, according to reporting cited by Snopes. The Pentagon had not clarified the application to female service members at the time of the announcement, as confirmed by multiple news sources.
What Doctors and Experts Say
The medical community has not broadly endorsed mass population screening for testosterone in asymptomatic individuals as a public health measure. Clinical guidelines from the Endocrine Society and the American Urological Association recommend testosterone testing when a patient presents with symptoms consistent with hypogonadism, not as a universal screen in healthy adults.
The rationale for symptom-triggered testing rather than mass screening reflects an important distinction in clinical medicine: population screening for a condition should meet several criteria, including that the condition is prevalent, that early detection meaningfully improves outcomes, and that the harms of false positives (including unnecessary treatment) do not outweigh the benefits of detection. For testosterone deficiency, this evidence base exists in symptomatic individuals but is less established for asymptomatic mass screening.
That said, the military context introduces relevant considerations that differ from routine civilian health care. Service members operate under chronic physical and physiological stress that can suppress hormonal function. They are required to meet demanding physical standards. A policy that identifies and offers treatment for genuine deficiency in this population is clinically different from a policy that simply normalizes testosterone therapy in healthy aging adults.
The policy also exists within a broader Trump administration effort to promote expanded public access to testosterone replacement therapies, according to NBC News, which noted the screening announcement as consistent with that larger posture.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Policy type: Mandatory annual testosterone blood test for service members over 30, added to existing Periodic Health Assessment; treatment (TRT) is voluntary if deficiency is found
- Clinical basis for testing: Recognized clinical condition (hypogonadism) that causes fatigue, muscle loss, mood disturbance, and other symptoms; treatable with testosterone replacement therapy when clinically indicated
- What medical guidelines say: The Endocrine Society and American Urological Association recommend testosterone testing when symptoms are present, not as routine mass screening in asymptomatic adults
- What the policy covers: All active-duty and reserve service members over 30; female service members over 30 appear included per the memo's text, though the Pentagon has not clarified this explicitly
- What it does not mandate: Testosterone replacement therapy; treatment is explicitly described as voluntary
- Context: This policy announcement is part of a broader Trump administration posture toward expanded access to testosterone therapies
- What readers should know: A blood test revealing a low testosterone number in an otherwise healthy person is not automatically a diagnosis requiring treatment. Clinical interpretation, symptom correlation, and physician evaluation are essential before treatment decisions are made
Who Is Affected?
The policy directly affects:
- All active-duty and reserve component service members aged 30 and older (approximately 700,000 to 800,000 individuals, based on DoD demographic data)
- Female service members, who appear to be included under the mandatory provision, though with sex-specific testosterone reference ranges that differ substantially from those applicable to men
- Service members found to have low testosterone through screening who may be offered and choose testosterone replacement therapy through military medical channels
For civilians, this policy does not directly apply, though it may raise awareness of testosterone testing options that individuals can discuss with their own primary care providers.
Symptoms of Low Testosterone to Know
The clinical picture of testosterone deficiency in men and women, when present, can include:
- Persistent fatigue and decreased energy
- Decreased muscle mass and strength
- Increased body fat, particularly around the abdomen
- Decreased libido
- Difficulty concentrating or brain fog
- Mood changes including depression or irritability
- Decreased bone density (increased fracture risk over time)
- In men: erectile dysfunction and reduced beard growth
- In women: reduced bone density, fatigue, and changes in mood and libido, though these often overlap with other hormonal changes
Experiencing some of these symptoms does not confirm testosterone deficiency; a blood test and clinical evaluation by a physician are required for diagnosis.
What You Can Do Now
- Service members who have questions about this new screening policy should speak with their unit's medical officer or primary military health care provider before their next Periodic Health Assessment.
- Service members who have experienced symptoms consistent with testosterone deficiency, such as unexplained fatigue, muscle loss, or mood changes, should raise these concerns with their military physician regardless of scheduled screening timelines.
- Civilians who believe they may have symptoms of low testosterone should speak with a primary care physician or endocrinologist. Testing is available through civilian health care, and clinical evaluation is the appropriate first step.
- Service members and civilians alike should be aware that a low testosterone reading on a blood test does not automatically indicate a need for treatment. Clinical judgment, symptom correlation, and physician guidance are required.
- Female service members with concerns about how this policy applies to them should seek clarification from their unit medical officer, as the Pentagon had not issued specific guidance on female inclusion as of July 20, 2026.
Cost and Access: What Patients Should Know
For military service members, all health care, including this new screening, is provided at no cost through the Military Health System and TRICARE. Testosterone replacement therapy, if prescribed and chosen, would similarly be covered through military medical channels.
For civilians interested in testosterone screening, a blood test can be ordered by a primary care physician and is covered by most insurance plans when there is a clinical indication. Out-of-pocket costs for testing without insurance coverage are generally modest (under $100 for standard hormone panels at major laboratory networks). However, testosterone replacement therapy for non-medically indicated use, such as lifestyle optimization, is not typically covered by insurance.
What Happens Next
The Pentagon will implement the screening program through existing Periodic Health Assessment infrastructure. The application of the mandatory provision to female service members is expected to be clarified in follow-up guidance. MedicalDaily will report on implementation details, any policy updates affecting female service members, and whether medical professional organizations respond formally to the policy's clinical framework.
The Bottom Line
The Pentagon's new mandatory testosterone screening policy adds a blood test to the annual health assessment already required of service members over 30, and makes testosterone replacement therapy available voluntarily to those found to have a deficiency. The policy is straightforward in what it requires: a blood draw. The medical questions it raises, including whether mass screening in asymptomatic populations is clinically supported and how the policy applies to female service members, are legitimate and deserve clear answers that the Pentagon has not yet fully provided.
